- Home
- CTNT vs CMND Comparison
CTNT vs CMND Comparison
Compare CTNT & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CTNT | CMND |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 4.0M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | CTNT | CMND |
|---|---|---|
| Price | $1.16 | $1.82 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 85.2K | ★ 117.6K |
| Earning Date | 11-07-2025 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,420,060.00 | N/A |
| Revenue This Year | $235.67 | N/A |
| Revenue Next Year | $20.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $1.74 |
| 52 Week High | $2.37 | $60.00 |
Technical Indicators
Market Signals| Indicator | CTNT | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 49.54 | 38.46 |
| Support Level | $1.09 | $2.12 |
| Resistance Level | $1.18 | $2.31 |
| Average True Range (ATR) | 0.08 | 0.23 |
| MACD | 0.00 | -0.13 |
| Stochastic Oscillator | 43.33 | 0.94 |
Price Performance
Historical ComparisonAbout CTNT Cheetah Net Supply Chain Service Inc.
Cheetah Net Supply Chain Service Inc is a one-stop services including Warehousing, Logistics, International trading & Supply Chain Finance, Etc. It operate in single segment Logistics and warehousing services which focuses on providing freight forwarding services for clients shipping goods from the U.S. to mainland China or Hong Kong. Its services include: (i) cargo storage, (ii) freight forwarding, (iii) U.S. customs clearance, and (iv) labor services and cargo loading and unloading.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.